Efficacy and Safety of Rimonabant as an Aid to Smoking Cessation With or Without Nicotine Patch
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
The primary objective is to compare the efficacy of rimonabant 20 mg OD fixed dose plus
nicotine patch 21 mg OD with the combination rimonabant 20 mg OD fixed dose plus placebo
patch on abstinence from smoking in cigarette smokers motivated to quit.
Secondary objectives are to evaluate the clinical and biological safety of rimonabant
associated with nicotine replacement therapy during a 9-week treatment period and to evaluate
the effect of the combination on weight and craving.